News Financials About Visit Website Latest News AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Apr. 17, 2024 9:00 AM ET ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M Apr. 10, 2024 8:36 AM ET ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M Mar. 26, 2024 8:35 AM ET More News Financials About Contact 510-668-0881 Visit Website AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars Mar. 21, 2024 8:30 AM ET ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine Mar. 19, 2024 8:34 AM ET ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update Mar. 14, 2024 9:34 AM ET ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars Feb. 27, 2024 8:30 AM ET ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues Feb. 15, 2024 8:30 AM ET ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) Feb. 12, 2024 8:30 AM ET ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Feb. 8, 2024 9:22 AM ET ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees Jan. 3, 2024 7:28 AM ET ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study Dec. 7, 2023 8:30 AM ET ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials Dec. 5, 2023 8:30 AM ET ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market Nov. 21, 2023 8:30 AM ET ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M Nov. 16, 2023 10:09 AM ET ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results Nov. 15, 2023 9:00 AM ET ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million Oct. 26, 2023 8:30 AM ET ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study Oct. 17, 2023 8:30 AM ET ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) Oct. 9, 2023 8:30 AM ET ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study Aug. 23, 2023 8:30 AM ET ABVC Executes Cooperation Agreement for Strategic Investments Aug. 17, 2023 9:22 AM ET ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement Aug. 10, 2023 8:30 AM ET ABVC Corporate Update and CEO's Letter to Shareholders Aug. 7, 2023 8:30 AM ET ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration Aug. 3, 2023 9:22 AM ET ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales Aug. 1, 2023 8:30 AM ET ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering Jul. 31, 2023 9:30 AM ET ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering Jul. 27, 2023 9:00 AM ET ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments Jul. 26, 2023 8:30 AM ET ABVC BioPharma Announces Reverse Stock Split Jul. 24, 2023 12:30 PM ET The New CEO of ABVC BioPharma Takes Steps to Help Improve Cash Efficiency Jul. 6, 2023 8:30 AM ET ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth Jun. 26, 2023 8:30 AM ET ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production Jun. 20, 2023 8:30 AM ET ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF Jun. 12, 2023 8:30 AM ET ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization Jun. 6, 2023 8:30 AM ET ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia May. 22, 2023 8:30 AM ET ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder May. 4, 2023 8:30 AM ET ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF Apr. 26, 2023 8:30 AM ET ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) Apr. 10, 2023 8:30 AM ET ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand Apr. 6, 2023 8:30 AM ET ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results Mar. 31, 2023 7:27 PM ET ABVC BioPharma Provides 2023 Pipeline Update Feb. 28, 2023 8:30 AM ET ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials Feb. 23, 2023 4:20 PM ET ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus (R) Feb. 21, 2023 8:30 AM ET ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference Jan. 19, 2023 8:30 AM ET FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer Jan. 5, 2023 8:30 AM ET ABVC BioPharma Provides Vitargus Update - Phase II Vitargus Study Protocol Received Thai FDA Approval Nov. 17, 2022 8:30 AM ET ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results Nov. 14, 2022 6:39 PM ET ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) Nov. 7, 2022 8:30 AM ET Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients Nov. 2, 2022 8:30 AM ET ABVC BioPharma Announces Vitargus Phase II Study Plan Approved by HREC in Australia Oct. 5, 2022 8:30 AM ET ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval Sep. 22, 2022 4:30 PM ET ABVC Biopharma Announces Letter to Shareholders Sep. 13, 2022 8:30 AM ET ABVC BioPharma Selects Additional Vitargus Phase II Study Site Sep. 9, 2022 8:30 AM ET ABVC Provides Oncology Pipeline Updates Aug. 22, 2022 8:30 AM ET ABVC BioPharma Provides Vitargus Update Aug. 18, 2022 8:30 AM ET ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results Aug. 15, 2022 4:35 PM ET ABVC BioPharma Provides Vitargus Update Aug. 2, 2022 8:30 AM ET ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028 Jul. 18, 2022 8:30 AM ET ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update Jul. 13, 2022 8:30 AM ET Zacks Places Share Value of ABVC BioPharma at $9.50 Jul. 6, 2022 8:30 AM ET ABVC BioPharma Provides Vitargus Update Jun. 30, 2022 8:30 AM ET ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation Jun. 21, 2022 8:30 AM ET ABVC BioPharma Submitted Vitargus Phase II Study Plan to Australia HREC Jun. 16, 2022 8:30 AM ET ABVC BioPharma Announces Termination of Two Contracts Jun. 10, 2022 8:30 AM ET ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study Jun. 1, 2022 8:30 AM ET ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners May. 25, 2022 8:30 AM ET Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines May. 23, 2022 7:30 AM ET ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results May. 16, 2022 6:00 PM ET ABVC BioPharma Engages the FreeMind Group to Support Grant Funding May. 13, 2022 8:30 AM ET ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering May. 12, 2022 8:30 AM ET ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated May. 10, 2022 8:30 AM ET ABVC BioPharma Announces Streamlined Vitargus(R) Manufacturing Process May. 5, 2022 8:30 AM ET ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed May. 3, 2022 8:30 AM ET ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study Apr. 28, 2022 8:30 AM ET ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting Apr. 26, 2022 8:30 AM ET ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results Mar. 31, 2022 4:05 PM ET ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference Mar. 23, 2022 9:25 AM ET ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study Feb. 2, 2022 8:00 AM ET ABVC BioPharma Selects Additional Vitargus Phase II Study Sites Jan. 5, 2022 8:30 AM ET ABVC BioPharma's Vitreous Substitute Vitargus Presented at 14th APVRS Congress Dec. 22, 2021 8:30 AM ET ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award Dec. 15, 2021 8:30 AM ET ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement Dec. 9, 2021 8:30 AM ET ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results Nov. 15, 2021 4:30 PM ET ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M Nov. 10, 2021 4:15 PM ET Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites Oct. 27, 2021 8:30 AM ET ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research Oct. 12, 2021 8:30 AM ET ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study Sep. 13, 2021 8:30 AM ET ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments Sep. 1, 2021 8:30 AM ET ABVC BioPharma Report Updated by Zacks/SCR Aug. 30, 2021 8:30 AM ET ABVC BioPharma Provides Vitargus Update Aug. 26, 2021 8:30 AM ET ABVC BioPharma Reports Second Quarter 2021 Results Aug. 12, 2021 8:40 AM ET ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering Aug. 3, 2021 8:30 AM ET American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021 Jan. 6, 2021 9:00 AM ET American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) Nov. 9, 2020 9:00 AM ET American BriVision Issues Clinical Study Report for Vitargus First-in-Human Phase I Clinical Trial Sep. 9, 2020 9:00 AM ET American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder Aug. 24, 2020 9:00 AM ET American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD Jul. 28, 2020 9:00 AM ET American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD Jun. 15, 2020 9:00 AM ET American BriVision Increases Size of Private Placement to Raise $2 Million May. 21, 2020 9:00 AM ET
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M Apr. 17, 2024 9:00 AM ET
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M Apr. 10, 2024 8:36 AM ET
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M Mar. 26, 2024 8:35 AM ET
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars Mar. 21, 2024 8:30 AM ET
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine Mar. 19, 2024 8:34 AM ET
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update Mar. 14, 2024 9:34 AM ET
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars Feb. 27, 2024 8:30 AM ET
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues Feb. 15, 2024 8:30 AM ET
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) Feb. 12, 2024 8:30 AM ET
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share Feb. 8, 2024 9:22 AM ET
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees Jan. 3, 2024 7:28 AM ET
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study Dec. 7, 2023 8:30 AM ET
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials Dec. 5, 2023 8:30 AM ET
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market Nov. 21, 2023 8:30 AM ET
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M Nov. 16, 2023 10:09 AM ET
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million Oct. 26, 2023 8:30 AM ET
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study Oct. 17, 2023 8:30 AM ET
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD) Oct. 9, 2023 8:30 AM ET
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement Aug. 10, 2023 8:30 AM ET
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration Aug. 3, 2023 9:22 AM ET
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales Aug. 1, 2023 8:30 AM ET
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering Jul. 31, 2023 9:30 AM ET
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering Jul. 27, 2023 9:00 AM ET
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments Jul. 26, 2023 8:30 AM ET
ABVC BioPharma Subsidiary BioKey Projects $1.0 Million Proceeds From Dietary Supplement Production Jun. 20, 2023 8:30 AM ET
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF Jun. 12, 2023 8:30 AM ET
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization Jun. 6, 2023 8:30 AM ET
ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia May. 22, 2023 8:30 AM ET
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder May. 4, 2023 8:30 AM ET
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF Apr. 26, 2023 8:30 AM ET
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC) Apr. 10, 2023 8:30 AM ET
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand Apr. 6, 2023 8:30 AM ET
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials Feb. 23, 2023 4:20 PM ET
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus (R) Feb. 21, 2023 8:30 AM ET
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference Jan. 19, 2023 8:30 AM ET
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer Jan. 5, 2023 8:30 AM ET
ABVC BioPharma Provides Vitargus Update - Phase II Vitargus Study Protocol Received Thai FDA Approval Nov. 17, 2022 8:30 AM ET
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD) Nov. 7, 2022 8:30 AM ET
Cedars-Sinai Medical Center Joins Phase I Clinical Study of ABVC BioPharma's Medication for Treating Depression in Cancer Patients Nov. 2, 2022 8:30 AM ET
ABVC BioPharma Announces Vitargus Phase II Study Plan Approved by HREC in Australia Oct. 5, 2022 8:30 AM ET
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval Sep. 22, 2022 4:30 PM ET
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results Aug. 15, 2022 4:35 PM ET
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028 Jul. 18, 2022 8:30 AM ET
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study Jun. 1, 2022 8:30 AM ET
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners May. 25, 2022 8:30 AM ET
Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines May. 23, 2022 7:30 AM ET
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed May. 3, 2022 8:30 AM ET
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study Apr. 28, 2022 8:30 AM ET
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting Apr. 26, 2022 8:30 AM ET
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study Feb. 2, 2022 8:00 AM ET
ABVC BioPharma's Vitreous Substitute Vitargus Presented at 14th APVRS Congress Dec. 22, 2021 8:30 AM ET
ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award Dec. 15, 2021 8:30 AM ET
ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement Dec. 9, 2021 8:30 AM ET
ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M Nov. 10, 2021 4:15 PM ET
ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research Oct. 12, 2021 8:30 AM ET
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study Sep. 13, 2021 8:30 AM ET
ABVC BioPharma, Inc. Announces Pricing of $6.875 Million Firm Commitment Offering Aug. 3, 2021 8:30 AM ET
American BriVision Issues Shareholder Letter Outlining Achievements of 2020 and Outlook for 2021 Jan. 6, 2021 9:00 AM ET
American BriVision Issues Clinical Study Report for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) Nov. 9, 2020 9:00 AM ET
American BriVision Issues Clinical Study Report for Vitargus First-in-Human Phase I Clinical Trial Sep. 9, 2020 9:00 AM ET
American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder Aug. 24, 2020 9:00 AM ET
American BriVision Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD Jul. 28, 2020 9:00 AM ET
American BriVision Announces Completed Patient Enrollment in Clinical Trial at UCSF for Treatment of Adult ADHD Jun. 15, 2020 9:00 AM ET
